Compare AMWL & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWL | MCRB |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.2M | 85.7M |
| IPO Year | 2020 | 2015 |
| Metric | AMWL | MCRB |
|---|---|---|
| Price | $7.69 | $7.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $7.40 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 60.6K | 50.9K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.06 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $6.56 |
| 52 Week High | $9.15 | $29.98 |
| Indicator | AMWL | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 72.92 | 43.53 |
| Support Level | $6.84 | $6.56 |
| Resistance Level | N/A | $9.53 |
| Average True Range (ATR) | 0.44 | 0.64 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 98.18 | 48.04 |
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.